Feedback / Questions
pro-doxorubicin (AVA6000) - Avacta
https://www.businesswire.com/news/home/20230621749596/en/Avacta-Announces-Successful-Completion-of-Fifth-Dose-Escalation-in-AVA6000-Phase-1-Clinical-Study
Jun 21, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next